Editors' Picks
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
At JPM 2025, companies like BlueRock Therapeutics, Ginkgo Bioworks, Tune Therapeutics, and Kyverna Therapeutics showcased their advancements in cell and gene therapies. BlueRock is progressing …
2025-01-21
Special
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
The U.S. Department of Health and Human Services (HHS) will allocate $590 million to Moderna to develop mRNA-based pandemic influenza vaccines. The funding will also …
2025-01-22
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
At JPM 2025, companies like BlueRock Therapeutics, Ginkgo Bioworks, Tune Therapeutics, and Kyverna Therapeutics showcased their advancements in cell and gene therapies. BlueRock is progressing …
2025-01-21
Building a Virtual Cell with AI: Key Priorities and Opportunities
Experts from Stanford University, Genentech, and the Chan-Zuckerberg Initiative are collaborating to create the virtual human cell, leveraging artificial intelligence (AI). The project aims to …
Building a Virtual Cell with AI: Key Priorities and Opportunities Read More »
2025-01-02
LATEST
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Deals
Ranking & Reports
Categories
China’s Laekna Joins Forces with Weight-Loss Giant Lilly on Muscle-Preserving Obesity Drug in Expanding $150B Market
2024-11-21
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
2024-06-24
ArriVent and Alphamab Partner in $615.5 Million Collaboration for Novel ADC Cancer Treatments
2024-06-06
Partner